When will the FDA reclassify BPC 157 to Category 1? Odds & Predictions The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157 Before and After: 1 Amazing Transformation FDA to Consider Lifting Restrictions on Numerous Compounded Peptides Foley & Lardner